Erica Wood

Out now in JAMA Cardiol: Clonal haematopoiesis of indeterminate potential (CHIP) not associated with higher risk of cardiovascular disease in ASPREE trial, but more clinically significant bleeding.

doi:10.1001/jamacardio.2025.3756

➡️ Three major RCTs (HEMOTION, TRAIN, SAHaRA) challenge restrictive transfusion dogma in brain injury.
➡️ Does the evidence now points toward a more liberal, neuroprotective threshold?

CCR Journal Watch
https://criticalcarereviews.com/latest-evidence/journal-watch

Addressing power gradients (gap between those with the most & least power in a team or system) is THE most effective lever for increasing psychological safety within a team. Many ways to take action for this:
psychsafety.com/reducing-pow.... By jadegarratt.bsky.social via tomgeraghty.bsky.social

Somatic preleukemic GATA1s mutations are acquired before birth in 25% of neonates with DS, and are not acquired postnatally. buff.ly/vKCMYCm #hemesky

WiLing Wednesday's Webinars are back! Join us for updates on various MCL topics presented by global experts, starting Oct 29 through to Nov 19.
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...

Looking forward to the next International Haemovigilance Network webinar on 21 October: "Partnering with patients is key to safer transfusion"
All are welcome, and it's free to register:
ihn-org.com/webinars/par...

Great to see the platelet findings from the prospective worldwide InPUT study of transfusion practice in intensive care. Just published in Crit Care Med.
doi: 10.1097/CCM.0000000000006880
@bloodsynergy.bsky.social

What is the implication of bulky disease on treatment and outcomes for patients with lymphoma? Read this analysis from the Australasian Lymphoma and Related Diseases Registry @lardr.bsky.social, led by Monash PhD student Eliza Chung.

haematologica.org/article/view...

⭐️⭐️⭐️ The 9500th participant ⭐️⭐️⭐️was recruited to the Lymphoma and Related Diseases Registry!
Congratulations and thanks to all participants, participating sites and staff, principal investigators and supporters.

Happy to be representing the Australian Haemoglobinopathy Registry at ASCA's 4th Sickle Cell Scientific Conference.
24 October 2025, in person at Perth Children's Hospital, or online.
Everyone is welcome!
More info/registration: aussicklecelladvocacy.org

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD!
📚 Identifying pediatric patients with sickle cell disease at high risk of experiencing chronic pain after HSCT
📖 Read the full article here. buff.ly/AgBdW37

Nice work, Dr Sarah Zhao!
Aust/NZ Myeloma & Related Diseases Registry real-world comparison of outcomes for older transplant-ineligible pts. Better PFS outcomes for first-line VRd than Rd or VCd. Prospective studies are needed to establish optimal induction therapy.
doi: 10.1016/j.clml.2025.08.004

Thanks @who.int for emphasising the importance of preventing and treating non-communicable diseases to improve outcomes for people worldwide

Hope you can join us, in person in Perth, or online, for the Myeloma and Related Diseases Registry annual breakfast meeting, this year on Mon 27 October as part of the Blood/ISBT conference.
All are welcome and there is no cost to attend.
More info/registration link:
www.mrdr.net.au/news/mrdr-an...

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, accor...

📰 New in research: Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors.

This important study adds to the growing evidence base on optimizing anticoagulant strategies to reduce recurrence risk: bit.ly/4lZwh7g

Looking forward to the Lymphoma & Related Diseases Registry @lardr.bsky.social annual breakfast meeting at BLOOD!
A partnership with Lymphoma Australia and Australasian Lymphoma Alliance.

In Perth + online on Tues 28 October.

Everyone is welcome!

Register: www.eventbrite.com.au/e/alalardrla...

Delighted to report that a new Centre of Research Excellence in supportive care for people with blood cancers (BloodCare) has been funded by the NHMRC!
Congratulations to chief investigator, Prof Zoe McQuilten and all our team.
Look forward to sharing more as we get started on this important work!

Can sickle red blood cells harm blood vessels without blocking them? Tomorrow’s ASH Journal Club explores how rigidity and altered shear stress spark vascular inflammation. Register now: https://bit.ly/4lbfEFV

#HemeSky #MedSky

Page 1 of article

Most viewed this week from JAMA: Restrictive platelet transfusion strategies are recommended to minimize adverse reactions, mitigate platelet shortages, reduce costs, and ensure patient-centric care.

ja.ma/45yYrkQ

Platelets shown to store DNA in study that could transform cancer Oxford-led study uncovers previously unknown function of platelets as DNA ‘vacuum cleaners’ in the blood, with profound implications for cancer diagnosis and prenatal screening.

NEW: Oxford researchers have discovered an unexpected and powerful new function for platelets.

Platelets act as scavengers, capturing and storing fragments of DNA that are circulating in the blood, including fetal DNA and mutated DNA from cancer cells. ⬇️
www.ox.ac.uk/news/2025-08...

Thanks to everyone who joined us, in person and online, for the OPTIMAL Centre of Research Excellence in improving immunoglobulin use workshop and open meeting.
Your participation is vital to the work of the CRE! You can find out more about us, and how to get involved, at: www.optimalcre.org

Register for next week's webinar
"Infections and Lymphoma - Post-treatment Risk for Infection" with Dr Sairah Ahmed, Dr Mini Kamboj-Gill, Dr Swetha Thiruvengadam, Dr Soni Smith and Dr Florence Broussais-Guillaumot

us06web.zoom.us/webinar/regi...

Lancet infographic outlining WHO targets and a three-point action plan for hepatitis elimination.

Globally, more than 300 million individuals are living with hepatitis B or C.

On #WorldHepatitisDay, explore a @lancetgastrohep.bsky.social Commission examining progress made towards hepatitis elimination & key themes that require further action to meet 2030 targets: tinyurl.com/2eexsumd

OPTIMAL @optimal-cre.bsky.social is an NHMRC Centre of Research Excellence in improving immunoglobulin use.
www.optimalcre.org

Our open meeting is coming up on Friday 1 August.
Everyone is welcome, in person (Melbourne 🇦🇺), or online.

More info + registration: 👉 OPTIMALCRE2025.eventbrite.com.au

Hope to see you in Perth for #BLOOD2025 and @isbt.bsky.social in October!

Do infectious agents drive lymphoma initiation?
Find out next week during the 3rd webinar of the Pathogens and Lymphoma Series with Catherine Thieblemont, Ayako Arai, Amira Marouf, Florence Broussais-Guillaumot and Sonali Smith
Register ➡️ us06web.zoom.us/webinar/regi...

Please join us for this Maddie Riewoldt's Vision online event on Wed 23 July to hear how patients and families can participate in the Aplastic Anaemia & Other Bone Marrow Failure Syndromes Registry and the Australian Marrow Failure Biobank

Register at www.mrv.org.au/research/scientific-events

Varicella zoster virus reactivation episodes and vaccination uptake in Spleen Australia registrants The Australian National Immunisation Program recently made the recombinant zoster vaccine (RZV), Shingrix, available to First Nations people (Aborigin…

Excited to share our 1st paper from our collaboration with @ianjohnwoolley.bsky.social & Spleen Australia is published! We describe predictors of VZV& shingles vaccine uptake in asplenia. Also a good reminder to all eligible adults to get their shingles vaccine! www.sciencedirect.com/science/arti...

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial url: academic.oup.com/jid/article-...

Please join us on Sat 19 July for the OPTIMAL Centre of Research Excellence in improving immunoglobulin use Kawasaki Disease Information Day for clinicians and families.
All welcome in person in Melbourne or online!
@optimal-cre.bsky.social
www.optimalcre.org/events or below for info/registration